Bloomberg Law
Drug, Device Manufacturers to Face Hill Scrutiny in 2019
January 8, 2019
Combating high drug and device prices is a bipartisan goal in Congress, and House Democrats in control of key oversight committees have made clear their plans to pursue investigations putting pharma CEOs under scrutiny. Manufacturers need to prep now to explain policies and prepare for public relations issues.
Capabilities
Suggested News & Insights
Sidley Medicaid Drug Rebate Program Summit Cocktail ReceptionMonday, October 5, 2026Sidley Healthcare Investment Conference 2026Tuesday, September 22, 2026Through the Looking Glass: What WHA79 Reveals About the Future of Global Life SciencesAugust 2026Switzerland Expands Integrity Rules to Medical Devices: Key Compliance Implications for Medtech CompaniesAugust 2026Second Circuit Clarifies Scope of “Property” that an FCA “Claim” May SeekAugust 17, 2026Sidley Earns Three Finalist Recognitions in The American Lawyer Industry Awards 2026August 17, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory